Exact Sciences Discloses Shareholder Lawsuits Challenging Abbott Merger, Provides Supplemental Proxy Details

summarizeSummary

Exact Sciences has filed additional proxy materials in response to shareholder lawsuits challenging its proposed acquisition by Abbott Laboratories, providing supplemental disclosures to its definitive proxy statement.

check_boxKey Events

• Shareholder Lawsuits Filed

  Three lawsuits have been initiated by purported stockholders in New York State court, alleging deficiencies in the definitive proxy statement related to the Abbott merger.

• Voluntary Supplemental Disclosures

  Exact Sciences is providing additional disclosures to address the lawsuits, aiming to avoid delays or adverse effects on the merger, without admitting liability.

• Updated Financial Analysis

  The supplemental disclosures include revisions to the Discounted Cash Flow, Selected Public Company, and Selected Precedent Transactions analyses performed by Centerview Partners.

• Revised Financial Projections

  Certain financial projections, including Adjusted EBITDA and Unlevered Free Cash Flow, have been updated due to a licensing agreement expense.

auto_awesomeAnalysis

This filing is highly important as it reveals that the proposed acquisition of Exact Sciences by Abbott Laboratories is facing legal challenges from shareholders. Three lawsuits have been initiated, alleging misleading information or omitted material details in the definitive proxy statement. While Exact Sciences believes these claims are without merit, it has voluntarily provided supplemental disclosures to mitigate litigation risks and prevent potential delays to the merger. These disclosures include updated financial analysis from Centerview Partners and revised financial projections, which are crucial for shareholders evaluating the fairness of the $105.00 per share cash offer. The presence of these lawsuits introduces uncertainty and potential delays to the merger timeline.